302 related articles for article (PubMed ID: 23657160)
1. Industry and regulatory performance in 2012: a year in review.
Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
[TBL] [Abstract][Full Text] [Related]
2. Re-engineering drug discovery and development.
FitzGerald GA
LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
[TBL] [Abstract][Full Text] [Related]
3. Medicine. Can intellectual property save drug development?
FitzGerald GA
Science; 2012 Oct; 338(6106):483-4. PubMed ID: 23112323
[No Abstract] [Full Text] [Related]
4. Drug-diagnostic co-development: how to harness the value.
Blair ED; Blakemore JA
Drug Discov Today; 2011 Oct; 16(19-20):902-5. PubMed ID: 21888987
[TBL] [Abstract][Full Text] [Related]
5. Can open-source drug R&D repower pharmaceutical innovation?
Munos B
Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
[TBL] [Abstract][Full Text] [Related]
6. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
Roman A
Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
[No Abstract] [Full Text] [Related]
7. A cheat sheet to navigate the complex maze of exclusivities in the United States.
Peng B; Tomas MC
Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306
[No Abstract] [Full Text] [Related]
8. Raising the bar for market authorisation of new drugs.
Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
[No Abstract] [Full Text] [Related]
9. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
Beatty PA; Laking GR
J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
[No Abstract] [Full Text] [Related]
10. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
11. Discontinued drugs in 2010: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
[TBL] [Abstract][Full Text] [Related]
12. The GAIN Act legislation to combat antimicrobial resistance: Where do we stand?
Sfeir MM
Infect Control Hosp Epidemiol; 2018 Dec; 39(12):1499-1500. PubMed ID: 30334503
[No Abstract] [Full Text] [Related]
13. Recent drug approvals from the US FDA and EMEA: what the future holds.
Pevarello P
Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
[TBL] [Abstract][Full Text] [Related]
14. Walking the drug regulatory tightrope.
Dove A
Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
[No Abstract] [Full Text] [Related]
15. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
16. Examining Manufacturing Readiness for Breakthrough Drug Development.
Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
[No Abstract] [Full Text] [Related]
17. [Regulatory aspects of biosimilars. Myths and facts].
Schneider CK; Weise M
Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
[TBL] [Abstract][Full Text] [Related]
18. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
Lanthier M; Miller KL; Nardinelli C; Woodcock J
Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
[TBL] [Abstract][Full Text] [Related]
19. Reinventing bioinnovation.
Kaitin KI; Honig PK
Clin Pharmacol Ther; 2013 Sep; 94(3):279-83. PubMed ID: 23963211
[TBL] [Abstract][Full Text] [Related]
20. 2013 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
[No Abstract] [Full Text] [Related]
[Next] [New Search]